Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Terminated 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urogenital Neoplasms 2Prostatic Neoplasms 2Prostatic Diseases 2Neoplasms by Site 2Neoplasms 2Male Urogenital Diseases 2Genital Neoplasms, Male 2Carcinoma 2Genital Diseases, Male 1Genital Diseases 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 280Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × padeliporfin × Clear all
NCT00707356 2016-04-19

Study of WST11 in Patients With Localized Prostate Cancer

Steba Biotech S.A.

Phase 2 Completed
42 enrolled
Genitourinary

Genital Diseases, Carcinoma, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT00975429 2015-04-28

Study Using WST11 in Patients With Localized Prostate Cancer

Steba Biotech S.A.

Phase 2 Completed
86 enrolled
Genitourinary

Carcinoma, Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡